CPHI: China Pharma Holdings, Inc. Stock

by  •  • Comments Off on CPHI: China Pharma Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4.84
Enterprise Value ($M) 7.93
Book Value ($M) 7.45
Book Value / Share 0.50
Price / Book 0.65
NCAV ($M) -3.02
NCAV / Share -0.20
Price / NCAV -1.60

Profitability (mra)
Return on Invested Capital (ROIC) -0.25
Return on Assets (ROA) -0.18
Return on Equity (ROE) -0.66

Liquidity (mrq)
Quick Ratio 0.33
Current Ratio 0.88

Balance Sheet (mrq) ($M)
Current Assets 6.00
Assets 16.47
Liabilities 9.01
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 7.01
Operating Income -2.75
Net Income -3.08
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.70
Cash from Investing -0.01
Cash from Financing 0.07

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-26 13G Liu Tao (Chengdu) 27.30
01-12 13G/A Streeterville Capital LLC 9.99 -36.19

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 ☐ TRANSITION REP
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-15 27,271 92,620 29.44
2024-05-14 52,955 276,318 19.16
2024-05-13 7,403 49,374 14.99
2024-05-10 85,723 227,146 37.74

(click for more detail)

Similar Companies
ATNM – Actinium Pharmaceuticals, Inc. AZTR – Azitra, Inc.
CLDI – Calidi Biotherapeutics, Inc. CVM – CEL-SCI Corporation
CYBN – Cybin Inc.


Financial data and stock pages provided by
Fintel.io